MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Ophthalmology, Optometry & Ocular Health (BioPharmaceuticals & Biotechnology)
Atsena Therapeutics
Organization & Developments: Atsena Therapeutics
Parents
Atsena Therapeutics
Children
*Atsena’s lead program is an investigational gene therapy dubbed ATSN-201 designed to treat X-linked retinoschisis (XLRS), an inherited eye condition that is typically diagnosed in childhood and can cause blindness
*Includes treatments for Leber congenital amaurosis and Usher syndrome and other inherited retinal disease.
*Ocular gene therapies designed to reverse or prevent blindness.
Atsena’s gene therapy has received fast track, rare pediatric disease and orphan drug tags from the FD
Jumps
Finance & Acquisition: Atsena Therapeutics
Key People: Atsena Therapeutics